Items where authors include "Lester, J.F."

Article

Bentham, R., Jones, T.P. orcid.org/0000-0003-2748-0780, Black, J.R.M. orcid.org/0000-0001-5598-7752 et al. (327 more authors) (2025) ImmuneLENS characterizes systemic immune dysregulation in aging and cancer. Nature Genetics, 57. pp. 694-705. ISSN 1061-4036

Biswas, D. orcid.org/0000-0001-9141-5188, Liu, Y.-H. orcid.org/0009-0001-1508-5276, Herrero, J. orcid.org/0000-0001-7313-717X et al. (267 more authors) (2025) Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma. Nature Cancer, 6. pp. 86-101. ISSN 2662-1347

Black, J.R.M. orcid.org/0000-0001-5598-7752, Bartha, G., Abbott, C.W. et al. (277 more authors) (2025) Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nature Medicine, 31 (1). pp. 70-76. ISSN 1078-8956

Puttick, C. orcid.org/0009-0006-3022-8737, Jones, T.P. orcid.org/0000-0003-2748-0780, Leung, M.M. orcid.org/0000-0001-9555-1080 et al. (279 more authors) (2024) MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution. Nature Genetics, 56. pp. 2121-2131. ISSN 1061-4036

Hobor, S., Al Bakir, M. orcid.org/0000-0002-0846-8332, Hiley, C.T. et al. (292 more authors) (2024) Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature Communications, 15. 4871. ISSN 2041-1723

Hynds, R.E. orcid.org/0000-0002-2170-8791, Huebner, A. orcid.org/0000-0001-8009-4999, Pearce, D.R. orcid.org/0000-0001-8443-2924 et al. (274 more authors) (2024) Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models. Nature Communications, 15 (1). 4653. ISSN 2041-1723

Pan, X., AbdulJabbar, K. orcid.org/0000-0002-4411-4435, Coelho-Lima, J. et al. (276 more authors) (2024) The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma. Nature Cancer, 5 (2). pp. 347-363. ISSN 2662-1347

Ng, K.W., Boumelha, J., Enfield, K.S.S. orcid.org/0000-0002-4551-6073 et al. (328 more authors) (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616. pp. 563-573. ISSN 0028-0836

Martínez-Ruiz, C. orcid.org/0000-0002-4817-0565, Black, J.R.M., Puttick, C. et al. (294 more authors) (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616. pp. 543-552. ISSN 0028-0836

Abbosh, C. orcid.org/0000-0002-8983-1382, Frankell, A.M. orcid.org/0000-0002-0341-7878, Harrison, T. et al. (303 more authors) (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616 (7957). pp. 553-562. ISSN 0028-0836

Frankell, A.M. orcid.org/0000-0002-0341-7878, Dietzen, M. orcid.org/0000-0002-6853-7563, Al Bakir, M. orcid.org/0000-0002-0846-8332 et al. (284 more authors) (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616. pp. 525-533. ISSN 0028-0836

Al Bakir, M. orcid.org/0000-0002-0846-8332, Huebner, A. orcid.org/0000-0001-8009-4999, Martínez-Ruiz, C. orcid.org/0000-0002-4817-0565 et al. (283 more authors) (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616. pp. 534-542. ISSN 0028-0836

Hill, W., Lim, E.L., Weeden, C.E. et al. (323 more authors) (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616 (7955). pp. 159-167. ISSN 0028-0836

Al-Sawaf, O. orcid.org/0000-0001-9895-0570, Weiss, J., Skrzypski, M. et al. (302 more authors) (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29 (4). pp. 846-858. ISSN 1078-8956

Karasaki, T. orcid.org/0000-0001-6863-2360, Moore, D.A. orcid.org/0000-0002-6296-1312, Veeriah, S. et al. (288 more authors) (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29 (4). pp. 833-845. ISSN 1078-8956

Hussain, S.A. orcid.org/0000-0003-1552-511X, Lester, J.F., Jackson, R. et al. (17 more authors) (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23 (5). pp. 650-658. ISSN 1470-2045

Fennell, D.A., Ewings, S., Ottensmeier, C. et al. (36 more authors) (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology, 22 (11). pp. 1530-1540. ISSN 1470-2045

Sanganalmath, P., Lester, J.E., Bradshaw, A.G. et al. (14 more authors) (2018) Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-Small Cell Lung Cancer (NSCLC): 7 Years' experience from nine UK centres. Clinical Oncology, 30 (3). pp. 144-150. ISSN 0936-6555

Bayman, N., Ardron, D., Ashcroft, L. et al. (12 more authors) (2016) Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ Open, 6 (1). ARTN e010589. e010589-e010589. ISSN 2044-6055